MedTrace Logo

PSMA-specific CAR-T Cell Therapy

NCT04429451 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-12

No results posted yet for this study

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

Conditions

  • PSMA Positive Tumors or Tumor Tissues

Interventions

BIOLOGICAL

4SCAR-PSMA T cells

Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV

Sponsors & Collaborators

  • Shenzhen Children's Hospital

    collaborator OTHER_GOV

  • The Seventh Affiliated Hospital of Sun Yat-sen University

    collaborator OTHER

  • Shenzhen Hospital of Southern Medical University

    collaborator OTHER

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-10-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429451 on ClinicalTrials.gov